Ipswich Investment Management Co. Inc. Buys 1,230 Shares of Eli Lilly and Company $LLY

Ipswich Investment Management Co. Inc. grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 21.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,995 shares of the company’s stock after acquiring an additional 1,230 shares during the quarter. Eli Lilly and Company accounts for approximately 1.2% of Ipswich Investment Management Co. Inc.’s portfolio, making the stock its 24th largest holding. Ipswich Investment Management Co. Inc.’s holdings in Eli Lilly and Company were worth $5,337,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in LLY. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company in the 1st quarter worth about $27,000. Sumitomo Mitsui Financial Group Inc. bought a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $27,000. Evolution Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $29,000. Steph & Co. grew its holdings in shares of Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after acquiring an additional 29 shares in the last quarter. Finally, Financial Gravity Companies Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $31,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.4%

Shares of Eli Lilly and Company stock opened at $1,071.35 on Friday. The stock has a market capitalization of $1.01 trillion, a P/E ratio of 52.41, a P/E/G ratio of 1.33 and a beta of 0.37. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The stock’s 50-day simple moving average is $960.76 and its 200 day simple moving average is $830.36.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter last year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is presently 29.35%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Berenberg Bank boosted their price objective on Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research report on Tuesday, December 2nd. Daiwa America upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Friday. The Goldman Sachs Group raised their price objective on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a report on Monday. Finally, HSBC reiterated a “hold” rating and issued a $1,070.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,141.73.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late‑stage trial win — Lilly’s oral GLP‑1 pill orforglipron met the primary and all key secondary endpoints in the ATTAIN‑MAINTAIN Phase 3 trial, showing patients who switched from Wegovy or Zepbound kept essentially all prior weight loss; Lilly has submitted orforglipron to the FDA for obesity. PR Newswire: Lilly’s orforglipron helped people maintain weight loss
• Positive Sentiment: Program momentum and regulatory progress — Chugai and other releases highlight positive topline Phase 3 results and Lilly’s FDA filing for orforglipron, reinforcing the company’s leadership in oral GLP‑1s. This raises prospects for rapid commercial adoption if approved. TipRanks: Chugai highlights positive Phase 3 results
• Positive Sentiment: Analyst upgrades and upside forecasts — Bank of America and other outlets point to improved quality metrics and forecast material upside (BofA cites potential multi‑billion sales for new oral obesity therapies), while Daiwa upgraded LLY — all supportive of higher valuations. Benzinga: BofA sees room for stock upside American Banking News: Daiwa upgrade
• Neutral Sentiment: Pipeline depth — Lilly advanced eloralintide into Phase 3, strengthening its obesity/diabetes pipeline beyond orforglipron; this is strategic for longer‑term growth but not an immediate revenue driver. TipRanks: Lilly advances eloralintide into Phase 3
• Neutral Sentiment: Branding/marketing initiatives — Lilly’s consumer outreach (e.g., Olympics tie‑ins) supports awareness for new therapies but has unclear near‑term financial impact. MM&M: Lilly debuts video featuring Team USA
• Negative Sentiment: Pricing pressure in Canada — Reuters reported Lilly cut prices of Mounjaro and Zepbound in Canada by ~20% or more, which could compress margins or reduce realized revenue per prescription in markets facing tougher pricing/regulatory scrutiny. Reuters: Lilly cuts price of diabetes, weight-loss drugs in Canada

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.